How much does a box of Laos generic capmatinib cost?

Capmatinib (Capmatinib), trade nameTabrecta, is a selective MET inhibitor developed by Novartis. It is mainly used For the treatment of patients with non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. The drug inhibits tumor cell proliferation and metastasis by targeting the MET signaling pathway and is suitable for first-line and previously treated patients. As one of the representative drugs of precision medicine, capmatinib has been granted breakthrough therapy certification by the US Food and Drug Administration (FDA) and approved for marketing.

The core indication of capmatinib is the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with skipping mutations in METgene exon 14. In clinical trials, capmatinib has shown a high overall response rate (ORR), especially in treatment-naïve patients, with response rates as high as 68%. In addition, the drug also shows good disease control rate (DCR), providing a new treatment option for some patients who are ineffective with traditional treatments.

Currently, capmatinib is not yet available in mainland China, and patients need to obtain the drug through legal overseas medical channels or international purchasing. The price of Novartis' original drugs is relatively expensive, mostly tens of thousands of yuan per box, which is a heavy financial burden for some patients. Therefore, generic drugs have become an economically viable alternative.

The price of generic capmatinib produced in Laos is relatively affordable, about3000 yuan per box. Despite their low prices, the ingredients of Lao generic drugs are basically the same as those of the original drugs, and their efficacy is equivalent. They are widely recognized by patients in some developing countries. When choosing generic drugs, it is recommended to purchase them through formal channels to ensure drug quality and safety.

Regardless of whether they choose the original drug or the generic drug, patients should undergo genetic testing to confirmMETexon14 before taking capmatinibThe existence of jump mutations. At the same time, regular follow-up and monitoring of adverse drug reactions are required during treatment. Since capmatinib may cause side effects such as nausea, vomiting, and abnormal liver function, patients should adjust the dose or take symptomatic treatment according to the doctor's recommendations.

xa0

Reference materials

Novartis official website:https://www.novartis.com